

8^{ème} Colloque Annuel du LabEx LERMIT
Vendredi 22 Novembre 2019
Amphithéâtre ImaGif, Campus CNRS, Gif-sur-Yvette

09:15 – 09:45 ***Ouverture***

Dr. Rodolphe FISCHMEISTER – Coordinateur du LabEx LERMIT

09:45 - 10:25 ***Conférence d'Ouverture***

Prof. Dr. Claus-Michael LEHR - Head of the "Drug Delivery" department at the Helmholtz Institute for Pharmaceutical Research Saarland, Germany, « *Titre à venir* »

10:25 - 12:10 ***Session Poster et Pause-Café***

En jeu : Prix du Jury & Prix Coup de Cœur du Public

12:10 – 13 :10 ***Mini-Symposium « Projets Interdisciplinaires au sein du LERMIT »***

3 communications

13:10 - 14:40 ***Déjeuner***

14:40 – 16:00 ***Mini-Symposium « Projets Prématuration et Emergences au sein du LERMIT »***

4 communications

16:00 – 16:30 ***Sessions Poster et Pause-Café***

En jeu : Prix du Jury & Prix Coup de Cœur du Public

16:30 – 17:20 ***Mini-Symposium « Projets de jeunes chercheurs du LERMIT »***

3 communications

17:20 – 18:00 ***Conférence de Clôture***

Dr. Andreas J. Kungl – Head of Biopharmaceutical Group at the Institute of Pharmaceutical Sciences, University of Graz, Austria « *Titre à venir* »

18:00 – 18:20 ***Remise des prix et Clôture***

Prix du Jury & Prix Coup de Cœur du Public

« TITRE A VENIR »

Prof Dr Claus-Michael Lehr

Head of the "Drug Delivery" department at the Helmholtz Institute for Pharmaceutical Research Saarland, Germany



Claus-Michael Lehr is Professor at Saarland University as well as cofounder and head of the department "Drug Delivery" at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), which was established as a branch of the Helmholtz Centre for Infection Research (HZI) Braunschweig in 2009. Prof. Lehr has also been cofounder of Across Barriers GmbH and acts as CEO of PharmBioTec GmbH, a non-for-profit contract research subsidiary of Saarland University.

The research theme of Prof. Lehr's team is non-invasive drug delivery across biological barriers, in particular the epithelia of the gastrointestinal tract, the skin and the lungs. Recently, this has been expanded to microbial barriers, such as the bacterial cellular envelope, biofilms and host cell membranes. A substantial part of the lab's activities is dedicated to innovative carriers systems, often based on nanotechnology, capable of safely and efficiently delivering drugs and vaccines across the barriers. In this context, the lab systematically investigates predictive cells and tissue models, preferentially human-based, to evaluate the safety and efficacy of novel therapeutic concepts and to facilitate their translation into the clinic.

Prof. Lehr is (co)author of more than 350 papers with >12.000 citations (h-index = 66). He is co-editor of the European Journal of Pharmaceutics and Biopharmaceutics and has been the initiator of the International Conference and Workshop "Biological Barriers", which takes place biannually at Saarland University. Recently, the British magazine "The Medicine Maker" rated him, for the third time, as one of the top 100 most influencing drug researchers in the world.

« TITRE À VENIR »

Prof. Andreas J. Kungl

Head of Biopharmaceutical Group at the Institute of Pharmaceutical Sciences, University of Graz, Austria



Professor Andreas J. Kungl studied biochemistry at Vienna University where he graduated in 1988. He did his PhD on ultrafast protein dynamics at the same University in the Departments of Genetics and Physical Chemistry. After working for two years as post-doc in protein X-ray crystallography at the Max-Planck-Institute of Biochemistry in Martinsried (with Prof. Robert Huber), Prof. Kungl joined in 1994 the Sandoz Research Institute in Vienna, which became subsequently Novartis Research Institute. His first industrial research projects were concerned with retroviral/HIV protein-RNA interactions, but he soon joined the dermatology department where he came for the first time into contact with chemokines and glycosaminoglycans. The interface between protein engineering and glycobiology

has been his prime focus of interest ever since.

Prof. Kungl has coordinated and was partner in several EU-funded projects and was a founding member of the Austrian Proteomics Platform. He is the Austrian representative to the “International Network of Protein Engineering Centres (INPEC)” which has >50 nodes around the world and which publishes the journal Protein Engineering and Design (PEDS), for which Prof. Kungl is Editor. He was recipient of an Austrian Academy of Sciences fellowship which enabled his habilitation for Biophysical Chemistry in 1999. In the same year he was appointed as Associate Professor at University of Graz where he became full Professor for Biopharmaceuticals and Proteomics in 2011. In 2005 Prof. Kungl was co-founder and Chief Scientific Officer of the spin-out company ProtAffinBiotechnologie AG. The company’s lead compound PA401, which he invented in 2004, reached Ph1 clinical investigation in 2011. His CellJammer© technology led to a platform of biopharmaceutical compounds which target glycosaminoglycans in inflammatory diseases.

With his research team, he tries to unravel the biological and physiological function of protein-glycan interactions. In addition, he is currently in the process of spinning out another biotech company in which a second generation of glycosaminoglycan-targeting biologics – the so-called GAGbodies™ – is developed for metastatic oncology indications.

Prof. Kungl is author of >100 original articles, reviews, and book chapters, and he is inventor of >20 patents.